GUTS
Fractyl Health, Inc. Common Stock
There isn't enough reported data to score GUTS yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
GUTS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Unavailable |
GUTS's revenue and profitability are currently weak. There isn't enough data to rate its cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
GUTS PE Valuation
GUTS has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
GUTS Forward outlook
There aren't enough analyst estimates for GUTS to show an outlook.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
GUTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$28.56 | -$11.64 |
| Q2 2025 | -$25.80 | -$9.60 |
| Q1 2025 | -$23.28 | -$3.84 |
| Q4 2024 | -$19.44 | +$0.96 |
| Q3 2024 | -$16.92 | +$1.44 |
| Q2 2024 | -$16.20 | -$0.12 |
| Q1 2024 | -$19.44 | -$6.72 |
| Q4 2023 | -$20.40 | -$6.48 |
HIMS has the stronger earnings trend. Trailing diluted EPS is down 269% for GUTS versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
GUTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $3K | -57% |
| Q3 2024 | $14K | -61% |
| Q2 2024 | $43K | -40% |
| Q1 2024 | $33K | +560% |
HIMS has the stronger quarterly revenue trend. Revenue is down 57% for GUTS versus up 49% for HIMS.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -840333% | -654891 points |
| Q3 2024 | -169957% | -131421 points |
| Q2 2024 | -53453% | -36960 points |
| Q1 2024 | -65279% | +176861 points |
| Q4 2023 | -185443% | N/A |
| Q3 2023 | -38536% | N/A |
| Q2 2023 | -16493% | N/A |
| Q1 2023 | -242140% | N/A |
GUTS's operating margin was −840333% last quarter, down 654890 points from the same quarter a year ago, near the bottom of its range since 2023.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
GUTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$21.3M | -$4.1M |
| Q3 2025 | -$22.7M | -$4.5M |
| Q2 2025 | -$21.3M | -$2.3M |
| Q1 2025 | -$25.5M | -$12.8M |
| Q4 2024 | -$17.3M | -$6.5M |
| Q3 2024 | -$18.3M | -$7.1M |
| Q2 2024 | -$19M | -$7.3M |
| Q1 2024 | -$12.8M | -$3.2M |
HIMS has the stronger cash trend. Its trailing FCF is down 84% versus its history, compared with GUTS at down 85%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
GUTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +29.3K shares |
| 1 year | +224% | +9.2M shares |
| 3 years | +233% | +9.3M shares |
| 5 years | +234% | +9.3M shares |
GUTS has 13M diluted shares, up 224% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over GUTS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
GUTS Net Leverage
GUTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
GUTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 24.9 | Oversold |
| Stochastic | 1.0 | Oversold |
GUTS's weekly RSI is 25 (oversold) and its Stochastic is 1 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
GUTS PE vs Healthcare Sector
GUTS has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
GUTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.56 | 68% below |
| 20 week MA | $6.17 | 87% below |
| 50 week MA | $9.75 | 92% below |
| 100 week MA | $13.9 | 94% below |
HIMS has stronger trend alignment. GUTS is above 0 of 4 weekly averages versus HIMS above 0 of 5.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
GUTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $154.2 | $23.6 | -85% |
| 2025 | $23.6 | $27.2 | +15% |
| 2026 YTD | $27.2 | $0.81 | -97% |
GUTS has finished lower in one of the last two years. It's down 97% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over GUTS on returns for 2026, with the stronger performance.